TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma

Reuters

2025/06/24

TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma

TAMPA, Fla., June 24, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA), a company at the forefront of Phase 3 immune-oncology research, has announced the initiation of its Phase 3 accelerated approval trial for IFx-2.0. This trial, focusing on patients with advanced or metastatic Merkel cell carcinoma (MCC), marks a significant milestone in TuHURA's efforts to enhance cancer immunotherapy. The trial is being conducted under a Special Protocol Assessment $(SPA.UK)$ agreement with the U.S. Food and Drug Administration (FDA). The initiation of this trial triggers the release of the third tranche of funds from a $12.5 million private placement financing, securing an additional $2.23 million for TuHURA. The financing is solely obtained by TuHURA Biosciences. This development is seen as a pivotal step in potentially overcoming resistance to checkpoint inhibitors in cancer treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16739) on June 24, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545284228"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545284228\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545284228?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545284228","market":"fut","top_or_hot":-1,"title":"TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TAMPA, Fla., June 24, 2025 - <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences, Inc.</a> (NASDAQ:HURA), a company at the forefront of Phase 3 immune-oncology research, has announced the initiation of its Phase 3 accelerated approval trial for IFx-2.0. This trial, focusing on patients with advanced or metastatic Merkel cell carcinoma (MCC), marks a significant milestone in TuHURA's efforts to enhance cancer immunotherapy. The trial is being conducted under a Special Protocol Assessment <a href=\"https://laohu8.com/S/SPA.UK\">$(SPA.UK)$</a> agreement with the U.S. Food and Drug Administration (FDA). The initiation of this trial triggers the release of the third tranche of funds from a $12.5 million private placement financing, securing an additional $2.23 million for TuHURA. The financing is solely obtained by TuHURA Biosciences. This development is seen as a pivotal step in potentially overcoming resistance to checkpoint inhibitors in cancer treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16739) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-24 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TAMPA, Fla., June 24, 2025 - <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences, Inc.</a> (NASDAQ:HURA), a company at the forefront of Phase 3 immune-oncology research, has announced the initiation of its Phase 3 accelerated approval trial for IFx-2.0. This trial, focusing on patients with advanced or metastatic Merkel cell carcinoma (MCC), marks a significant milestone in TuHURA's efforts to enhance cancer immunotherapy. The trial is being conducted under a Special Protocol Assessment <a href=\"https://laohu8.com/S/SPA.UK\">$(SPA.UK)$</a> agreement with the U.S. Food and Drug Administration (FDA). The initiation of this trial triggers the release of the third tranche of funds from a $12.5 million private placement financing, securing an additional $2.23 million for TuHURA. The financing is solely obtained by TuHURA Biosciences. This development is seen as a pivotal step in potentially overcoming resistance to checkpoint inhibitors in cancer treatment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16739) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HURA","symbol_name":"TuHURA Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL2mzcpp:1","article_id":"2545284228","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545284228","pubTimestamp":1750766504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on June 24, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HURA":"TuHURA Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"TuHURA Biosciences在启动IFx-2.0治疗晚期默克尔细胞癌的3期试验后获得223万美元资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HURA":0.9},"content_text":"TuHURA Biosciences Secures $2.23 Million Funding Tranche Following Initiation of Phase 3 Trial for IFx-2.0 in Advanced Merkel Cell Carcinoma\n    \n\n        TAMPA, Fla., June 24, 2025 - TuHURA Biosciences, Inc. (NASDAQ:HURA), a company at the forefront of Phase 3 immune-oncology research, has announced the initiation of its Phase 3 accelerated approval trial for IFx-2.0. This trial, focusing on patients with advanced or metastatic Merkel cell carcinoma (MCC), marks a significant milestone in TuHURA's efforts to enhance cancer immunotherapy. The trial is being conducted under a Special Protocol Assessment $(SPA.UK)$ agreement with the U.S. Food and Drug Administration (FDA). The initiation of this trial triggers the release of the third tranche of funds from a $12.5 million private placement financing, securing an additional $2.23 million for TuHURA. The financing is solely obtained by TuHURA Biosciences. This development is seen as a pivotal step in potentially overcoming resistance to checkpoint inhibitors in cancer treatment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16739) on June 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}